BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 12360485)

  • 1. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles.
    Fickert P; Zollner G; Fuchsbichler A; Stumptner C; Weiglein AH; Lammert F; Marschall HU; Tsybrovskyy O; Zatloukal K; Denk H; Trauner M
    Gastroenterology; 2002 Oct; 123(4):1238-51. PubMed ID: 12360485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice.
    Fickert P; Fuchsbichler A; Wagner M; Zollner G; Kaser A; Tilg H; Krause R; Lammert F; Langner C; Zatloukal K; Marschall HU; Denk H; Trauner M
    Gastroenterology; 2004 Jul; 127(1):261-74. PubMed ID: 15236191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice.
    Wagner M; Fickert P; Zollner G; Fuchsbichler A; Silbert D; Tsybrovskyy O; Zatloukal K; Guo GL; Schuetz JD; Gonzalez FJ; Marschall HU; Denk H; Trauner M
    Gastroenterology; 2003 Sep; 125(3):825-38. PubMed ID: 12949728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice.
    Fickert P; Wagner M; Marschall HU; Fuchsbichler A; Zollner G; Tsybrovskyy O; Zatloukal K; Liu J; Waalkes MP; Cover C; Denk H; Hofmann AF; Jaeschke H; Trauner M
    Gastroenterology; 2006 Feb; 130(2):465-81. PubMed ID: 16472600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of mdr2 mutation with combined tandem disruption of canalicular glycoprotein transporters by cyclosporine A on bile formation in mice.
    Elamiri A; Perwaiz S; Tuchweber B; Yousef IM
    Pharmacol Res; 2003 Nov; 48(5):467-72. PubMed ID: 12967592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolism and effects on cholestasis of isoursodeoxycholic and ursodeoxycholic acids in bile duct ligated rats.
    Purucker E; Marschall HU; Winograd R; Matern S
    Biochim Biophys Acta; 2001 Apr; 1526(1):44-52. PubMed ID: 11287121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between biliary lipid and protoporphyrin secretion; potential role of mdr2 P-glycoprotein in hepatobiliary organic anion transport.
    Beukeveld GJ; In 't Veld G; Havinga R; Groen AK; Wolthers BG; Kuipers F
    J Hepatol; 1996 Mar; 24(3):343-52. PubMed ID: 8778203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Ursodeoxycholate and cholate feeding on liver disease in FVB mice with a disrupted mdr2 P-glycoprotein gene.
    Van Nieuwkerk CM; Elferink RP; Groen AK; Ottenhoff R; Tytgat GN; Dingemans KP; Van Den Bergh Weerman MA; Offerhaus GJ
    Gastroenterology; 1996 Jul; 111(1):165-71. PubMed ID: 8698195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bile acids modulate colonic MAdCAM-1 expression in a murine model of combined cholestasis and colitis.
    Gao RY; Shearn CT; Orlicky DJ; Battista KD; Alexeev EE; Cartwright IM; Lanis JM; Kostelecky RE; Ju C; Colgan SP; Fennimore BP
    Mucosal Immunol; 2021 Mar; 14(2):479-490. PubMed ID: 33004979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver.
    Fickert P; Zollner G; Fuchsbichler A; Stumptner C; Pojer C; Zenz R; Lammert F; Stieger B; Meier PJ; Zatloukal K; Denk H; Trauner M
    Gastroenterology; 2001 Jul; 121(1):170-83. PubMed ID: 11438506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effect of treating pregnant rats with ursodeoxycholic acid on the congenital impairment of bile secretion induced in the pups by maternal cholestasis.
    Macias RI; Serrano MA; Monte MJ; Jimenez S; Hernandez B; Marin JJ
    J Pharmacol Exp Ther; 2005 Feb; 312(2):751-8. PubMed ID: 15452192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of ursodeoxycholic acid, glutamine and polyclonal immunoglobulins on bacterial translocation in common bile duct ligated rats.
    Aldemir M; Geyik MF; Kökoğlu OF; Büyükbayram H; Hoşoğlu S; Yağmur Y
    ANZ J Surg; 2003 Sep; 73(9):722-6. PubMed ID: 12956789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dietary cholesterol does not normalize low plasma cholesterol levels but induces hyperbilirubinemia and hypercholanemia in Mdr2 P-glycoprotein-deficient mice.
    Voshol PJ; Koopen NR; de Vree JM; Havinga R; Princen HM; Elferink RP; Groen AK; Kuipers F
    J Hepatol; 2001 Feb; 34(2):202-9. PubMed ID: 11281547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New therapeutical indications of ursodeoxycholic acid.
    Copaci I; Micu L; Iliescu L; Voiculescu M
    Rom J Gastroenterol; 2005 Sep; 14(3):259-66. PubMed ID: 16200237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of ursodeoxycholic acid administration on bile duct proliferation and cholestasis in bile duct ligated rat.
    Frezza EE; Gerunda GE; Plebani M; Galligioni A; Giacomini A; Neri D; Faccioli AM; Tiribelli C
    Dig Dis Sci; 1993 Jul; 38(7):1291-6. PubMed ID: 8325189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ursodeoxycholate further increases bile-duct cell proliferative response induced by partial bile-duct ligation in rats.
    Barone M; Maiorano E; Ladisa R; Pece A; Berloco P; Strazzabosco M; Caruso ML; Valentini AM; Ierardi E; Di Leo A; Francavilla A
    Virchows Arch; 2004 Jun; 444(6):554-60. PubMed ID: 15071740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ursodeoxycholic acid choleresis: relationship to biliary HCO-3 and effects of Na+-H+ exchange inhibitors.
    Renner EL; Lake JR; Cragoe EJ; Van Dyke RW; Scharschmidt BF
    Am J Physiol; 1988 Feb; 254(2 Pt 1):G232-41. PubMed ID: 2831731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ursodeoxycholic acid treatment of vanishing bile duct syndromes.
    Pusl T; Beuers U
    World J Gastroenterol; 2006 Jun; 12(22):3487-95. PubMed ID: 16773706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of ursodeoxycholic acid in patients with liver disease.
    Angulo P
    Curr Gastroenterol Rep; 2002 Feb; 4(1):37-44. PubMed ID: 11825540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cells.
    He H; Mennone A; Boyer JL; Cai SY
    Hepatology; 2011 Feb; 53(2):548-57. PubMed ID: 21274875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.